Tech Company Financing Transactions
Sopherion Therapeutics Funding Round
On 9/6/2004, Sopherion Therapeutics raised $47 million in Series B investment from TL Ventures, Canaan Partners and NewSpring Capital.
Transaction Overview
Company Name
Announced On
9/6/2004
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series B
Investors
TL Ventures (Lead Investor) (Marc Ostro)
Proceeds Purpose
the proceeds of the Series B will be used to validate a widely applicable lead discovery platform and to fortify Sopherion's infrastructure.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
104 Carnegie Center 200
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Website
Email Address
Overview
Sopherion Therapeutics, Inc. is a biopharmaceutical company focusing on the development and commercialization of anti-cancer therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ronald Goldfarb
Executive Vice President
Marcel Rozencweig
VP - Finance
Alina Groblicka
VP - Regulatory Affairs
Salvatore Forenza
Browse more venture capital transactions:
Prev: 9/3/2004: MediciNova venture capital transaction
Next: 9/7/2004: Atrua Technologies venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs